Today: 21 May 2026
AppLovin stock rises after Needham upgrade sets $700 target as Feb. 11 earnings loom
27 January 2026
2 mins read

AppLovin stock rises after Needham upgrade sets $700 target as Feb. 11 earnings loom

New York, January 26, 2026, 18:19 EST — After-hours

  • AppLovin shares climb following Needham’s upgrade to buy, citing improved e-commerce ad trends
  • Needham boosts its 2026 e-commerce revenue outlook, highlighting fresh advertiser gains
  • Attention turns to the February 11 earnings, while the Fed’s midweek decision looms in the backdrop

AppLovin Corp (APP.O) shares climbed 2.2% to $535.44 in after-hours Monday, building on momentum from a broker upgrade linked to its e-commerce ad strategy. The stock fluctuated between $520 and $558 throughout the session.

The move comes as investors seek evidence that AppLovin’s Axon ad-targeting tools can grow past mobile gaming, the company’s original stronghold. E-commerce ads represent a larger market, but budgets shift fast when the figures falter.

Needham & Company bumped AppLovin to buy from hold on Monday, upping its price target to $700. The firm cited fresh analysis boosting confidence in 2026 e-commerce revenue growth. It raised the 2026 e-commerce revenue forecast to $1.45 billion from $1.05 billion and projects first-quarter e-commerce revenue to climb to $251 million from $191 million in Q4. “We upgrade APP to Buy… giving us more confidence in the trajectory of ecommerce revenue growth in ’26E,” the broker said. Investing.com

Advertising firms usually experience a slower start to the year after the holiday spike — the so-called “seasonality” analysts mention — so any quarter-on-quarter rise stands out. Needham highlighted better ad formats too, like playable ads and rewarded video, where users earn in-app rewards for watching.

Needham has been digging for new evidence online. It spotted names like prediction-market platform Kalshi and online marketplace Etsy either using or testing AppLovin’s Axon technology, along with several other advertisers. The firm identified 435 brands employing its Axon Pixel plug-in as of Jan. 21, up from 431 in late December and 359 last March, after scanning over 2,200 websites. Analyst Bernie McTernan commented, “We think they are in the process of showing they can be successful outside of games too.” AppLovin shares more than doubled in 2025 but have dropped about 20% so far this year, the report noted. Barron’s

A “pixel” is a tiny snippet of code that lets advertisers track if an ad resulted in a sale or another action. AppLovin’s plug-in, which can be added via platforms like Shopify or Alphabet’s Google tools, offers merchants a self-serve way to connect with its ad network.

Investors are bracing for the Federal Reserve’s two-day policy meeting, wrapping up Wednesday, with expectations firmly set on rates holding steady at 3.50%-3.75%. This is crucial for growth stocks sensitive to interest rates, where valuations play a key role.

AppLovin still faces regulatory scrutiny. Reuters reported in October that the U.S. Securities and Exchange Commission is investigating its data-collection practices. Bloomberg News had earlier said the probe stemmed from a whistleblower complaint and short-seller reports. So far, the SEC hasn’t accused AppLovin or its executives of any wrongdoing, and the investigation’s current status remains unclear.

E-commerce advertising is a crowded space. Google, Meta, and Amazon dominate performance marketing, while smaller ad-tech firms scramble to secure budgets as brands pull back on spending.

AppLovin plans to release its fourth-quarter and full-year 2025 earnings on Feb. 11, after U.S. markets close. Management will follow up with a webinar the same day. Investors will be keen to hear updates on e-commerce revenue, advertiser uptake, and any comments on the regulatory environment.

Stock Market Today

  • Bitmine Immersion Technologies Uplists to NYSE, Holds 5M+ ETH as Ethereum Proxy, Launches MAVAN Staking
    May 21, 2026, 12:11 AM EDT. Bitmine Immersion Technologies (NYSE:BMNR) has become a major Ethereum proxy by accumulating over 5 million ETH, representing more than 4.3% of Ethereum's total supply. The company uplisted to the NYSE and introduced MAVAN, an institutional-grade Ethereum staking platform, shifting its focus beyond mining to include staking services. BMNR stock closed at $19.39, trading below analyst targets and experiencing recent price declines despite longer-term gains. Investors should watch Ethereum price trends, staking yields, and institutional adoption of MAVAN, while noting BMNR remains loss-making and has diluted shareholders.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
Palo Alto Networks stock climbs after the bell as Fed decision nears — what traders watch next
Previous Story

Palo Alto Networks stock climbs after the bell as Fed decision nears — what traders watch next

Exxon Mobil stock dips after hours as Baytown freeze and carbon-capture launch set up earnings week
Next Story

Exxon Mobil stock dips after hours as Baytown freeze and carbon-capture launch set up earnings week

Go toTop